Daytime use of closed-loop insulin delivery increased time spent with glucose concentration in the target range by 8·1 percentage points (95% CI 5·3–11·0, p<0·0001) and reduced the burden of hypoglycaemia by 61% (14–75, p=0·0001). Here, INS is linked to Hypoglycemia.